238 related articles for article (PubMed ID: 37347276)
21. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW; Brundin P
Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
[TBL] [Abstract][Full Text] [Related]
22. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
23. Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains.
Walker DG; Lue LF; Adler CH; Shill HA; Caviness JN; Sabbagh MN; Akiyama H; Serrano GE; Sue LI; Beach TG;
Exp Neurol; 2013 Feb; 240():190-204. PubMed ID: 23201181
[TBL] [Abstract][Full Text] [Related]
24. Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease.
Covell DJ; Robinson JL; Akhtar RS; Grossman M; Weintraub D; Bucklin HM; Pitkin RM; Riddle D; Yousef A; Trojanowski JQ; Lee VM
Neuropathol Appl Neurobiol; 2017 Dec; 43(7):604-620. PubMed ID: 28386933
[TBL] [Abstract][Full Text] [Related]
25. The subcellular arrangement of alpha-synuclein proteoforms in the Parkinson's disease brain as revealed by multicolor STED microscopy.
Moors TE; Maat CA; Niedieker D; Mona D; Petersen D; Timmermans-Huisman E; Kole J; El-Mashtoly SF; Spycher L; Zago W; Barbour R; Mundigl O; Kaluza K; Huber S; Hug MN; Kremer T; Ritter M; Dziadek S; Geurts JJG; Gerwert K; Britschgi M; van de Berg WDJ
Acta Neuropathol; 2021 Sep; 142(3):423-448. PubMed ID: 34115198
[TBL] [Abstract][Full Text] [Related]
26. Lewy Bodies and the Mechanisms of Neuronal Cell Death in Parkinson's Disease and Dementia with Lewy Bodies.
Power JH; Barnes OL; Chegini F
Brain Pathol; 2017 Jan; 27(1):3-12. PubMed ID: 26667592
[TBL] [Abstract][Full Text] [Related]
27. α-Synuclein and Lewy pathology in Parkinson's disease.
Kalia LV; Kalia SK
Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
Lee VM; Trojanowski JQ
Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
[TBL] [Abstract][Full Text] [Related]
29. TRAF6 promotes atypical ubiquitination of mutant DJ-1 and alpha-synuclein and is localized to Lewy bodies in sporadic Parkinson's disease brains.
Zucchelli S; Codrich M; Marcuzzi F; Pinto M; Vilotti S; Biagioli M; Ferrer I; Gustincich S
Hum Mol Genet; 2010 Oct; 19(19):3759-70. PubMed ID: 20634198
[TBL] [Abstract][Full Text] [Related]
30. Formation and development of Lewy pathology: a critical update.
Jellinger KA
J Neurol; 2009 Aug; 256 Suppl 3():270-9. PubMed ID: 19711116
[TBL] [Abstract][Full Text] [Related]
31. Variable expression of mitochondrial complex IV in the course of nigral intracellular accumulation of α-synuclein.
Lang A; Dassler E; Milenkovic I; Lutz MI; Kovacs GG
Parkinsonism Relat Disord; 2021 Sep; 90():57-61. PubMed ID: 34385008
[TBL] [Abstract][Full Text] [Related]
32. Degeneration of dopaminergic circuitry influences depressive symptoms in Lewy body disorders.
Patterson L; Rushton SP; Attems J; Thomas AJ; Morris CM
Brain Pathol; 2019 Jul; 29(4):544-557. PubMed ID: 30582885
[TBL] [Abstract][Full Text] [Related]
33. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain.
Roberts RF; Wade-Martins R; Alegre-Abarrategui J
Brain; 2015 Jun; 138(Pt 6):1642-57. PubMed ID: 25732184
[TBL] [Abstract][Full Text] [Related]
34. An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology.
Wider C; Ross OA; Nishioka K; Heckman MG; Vilariño-Güell C; Jasinska-Myga B; Erketin-Taner N; Rademakers R; Graff-Radford NR; Mash DC; Papapetropoulos S; Duara R; Uchikado H; Wszolek ZK; Farrer MJ; Dickson DW
J Neurol Neurosurg Psychiatry; 2012 Apr; 83(4):424-9. PubMed ID: 22291217
[TBL] [Abstract][Full Text] [Related]
35. Degeneration process of Lewy bodies in the brains of patients with dementia with Lewy bodies using alpha-synuclein-immunohistochemistry.
Iseki E; Marui W; Akiyama H; Uéda K; Kosaka K
Neurosci Lett; 2000 May; 286(1):69-73. PubMed ID: 10822155
[TBL] [Abstract][Full Text] [Related]
36. Transcriptomic signatures of brain regional vulnerability to Parkinson's disease.
Keo A; Mahfouz A; Ingrassia AMT; Meneboo JP; Villenet C; Mutez E; Comptdaer T; Lelieveldt BPF; Figeac M; Chartier-Harlin MC; van de Berg WDJ; van Hilten JJ; Reinders MJT
Commun Biol; 2020 Mar; 3(1):101. PubMed ID: 32139796
[TBL] [Abstract][Full Text] [Related]
37. Is Braak staging valid for all types of Parkinson's disease?
Jellinger KA
J Neural Transm (Vienna); 2019 Apr; 126(4):423-431. PubMed ID: 29943229
[TBL] [Abstract][Full Text] [Related]
38. Spreading of alpha-synuclein - relevant or epiphenomenon?
Killinger BA; Kordower JH
J Neurochem; 2019 Sep; 150(5):605-611. PubMed ID: 31152606
[TBL] [Abstract][Full Text] [Related]
39. [Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies].
Orimo S
Rinsho Shinkeigaku; 2008 Jan; 48(1):11-24. PubMed ID: 18386627
[TBL] [Abstract][Full Text] [Related]
40. Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease.
Ren Q; Ma M; Yang J; Nonaka R; Yamaguchi A; Ishikawa KI; Kobayashi K; Murayama S; Hwang SH; Saiki S; Akamatsu W; Hattori N; Hammock BD; Hashimoto K
Proc Natl Acad Sci U S A; 2018 Jun; 115(25):E5815-E5823. PubMed ID: 29735655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
